Introduction
============

The profound and multiple benefits of living a physically active lifestyle extend to older adults and special populations (living with disability and/or chronic illness that may limit mobility and/or physical endurance) \[[@B1]\]. In reviewing their 2008 release of federal physical activity guidelines, the U.S. Advisory Committee Report concluded that, in addition to the well known cardiovascular and metabolic health benefits, there was \"strong evidence\" that physically active older adults have higher levels of functional health, lower risks of falling, and improved cognitive health \[[@B2]\]. A recent systematic review further confirmed that greater aerobic physical activity was associated with reduced risk of functional limitations and disability with age \[[@B3]\]. A systematic review of the benefits of physical activity for special populations is lacking, but it is presumed that similar returns are reasonable to expect.

Evidence-based guidelines for older adults communicate the benefits of a physically active lifestyle using frequency-, duration-, and intensity-based parameters. Similar to what is typically communicated to younger adults, public health physical activity guidelines promote at least 150 minutes/week of moderate-to-vigorous physical activity (MVPA) for older adults and include \"brisk walking\" as a primary example of an appropriate activity \[[@B3]\]. Variations on the message exist: the World Health Organization promotes at least 30 minutes of moderate intensity physical activity 5 days per week for older adults \[[@B4]\]. All older adults should avoid inactivity and some physical activity is considered better than none \[[@B5]\]; however, public health recommendations answer a pragmatic need to provide generalized guidance. Regardless of the message specifics, as framed, time- and intensity-based guidelines imply that this dose of physical activity should be taken *over and above*a baseline level which is yet to be quantified. This is problematic, since it is likely that this baseline level of non-exercise physical activity has been most susceptible to secular transitions in occupation in favour of desk jobs and reductions in physical demands of most other jobs, reliance on labour-saving devices to supplement or replace domestic tasks and other activities of daily living, dependence on motorized transportation, and an insidious and pervasive predilection for passive leisure time pursuits \[[@B6]\]. Since self-reported leisure time physical activity (specifically walking for exercise) increases in older adults with age \[[@B7]\], yet objectively monitored physical activity decreases \[[@B8]\], it is also likely that this baseline level of non-exercise physical activity is vulnerable to advancing age, disability, and chronic illness.

Step counting devices (i.e., pedometers and accelerometers) provide a means of objectively quantifying total daily activity, and their counting mechanisms are particularly sensitive to detecting the recommended intensities of walking believed to be associated with a host of healthful outcomes for older adults. Accelerometers can provide additional data with regards to time spent in various intensities of physical activity and inactivity in addition to providing step data. However, due to their relative expense and associated intensive data management requirements their use is typically limited to research. In contrast, simple and inexpensive pedometers, even if they are less sensitive to very slow walking \[[@B9]\], are more likely to be adopted for clinical and real world applications, including direct use by members of the public. Regardless of instrumentation choice, the utility of any step output is limited without the ability to translate public health guidelines in terms of steps/day.

Methods
=======

The Public Health Agency of Canada (PHAC) commissioned a literature review in February 2010 to inform an evidence-based approach to converting step count data into minutes of active time congruent with public health guidelines. An English-language search strategy identified 1,594 articles published since 2000 using the keywords (pedomet\* or acceleromet\*) and step\* and ((physical activity) or walk\*) within the following search engines: CINAHL, ERIC, MEDLINE, PsycINFO, SocINDEX, and SPORTDiscus. The list was subsequently reduced to 837 articles after duplicates, remaining non-English language articles, dissertations, non-peer reviewed articles, and those obviously not dealing with step-defined human physical activity were removed. Abstracts were reviewed, identified articles were assembled, and a report was written. Selected researchers from around the world with first-hand experience collecting step data in the relevant population were invited to critically review the report, identify any gaps or offer additional literature, check and verify data pulled from original sources, and intellectually contribute to this consensus article.

For the purposes of this article, we defined older adults as those older than 65 years of age, although much of the identified literature represents even older individuals. At times we considered studies that included at least some participants under 65 years of age, for example, as low as 50 years of age if the sample mean age was over 65 years of age. The definition of special populations was purposely quite broad and included studies of individuals living with disability and/or chronic illness that may limit mobility and/or physical endurance. Older adults with disabilities or chronic health problems, and frail older adults would more appropriately fit into the special populations category, however, this category is not necessarily defined solely by age. The final product herein is centred on the literature relevant to older adults and special populations with regards to: 1) normative data (i.e., expected values); 2) changes expected from interventions; 3) controlled studies that determine exact step-based conversions of timed behaviour; 4) computing a step translation of time- and intensity-based physical activity guidelines (e.g., steps/day associated with time in moderate-to-vigorous physical activity or MVPA); 5) directly measured steps/day indicative of minimal time in MVPA taken under free-living conditions; and, 6) steps/day associated with various health outcomes. Each section represents a \'mini-review.\' At times the search strategy was exhaustive and the exact number of articles identified is presented under the appropriate heading below (e.g., direct studies of step-equivalents of physical activity guidelines). Where current reviews were identified (e.g., normative data), the findings were simply summarized herein and select original articles were referred to only to make specific points. Where appropriate, details of studies were tabulated. Any apparent inconsistencies in reporting within tables (e.g., instrument brand, model, manner in which participant age is reported, etc.) reflect reporting inconsistencies extracted directly from original articles. The child/adolescent \[[@B10]\] and adult populations \[[@B11]\] literature is reviewed separately.

Results
=======

Normative data (expected values)
--------------------------------

An early review of normative data from studies published between 1980 and 2000 \[[@B12]\] reported that we can expect 1) healthy older adults to take 6,000-8,500 steps/day (based on 10 studies identified that included adults age 50+ years with no specifically reported disabilities or chronic conditions); and 2) special populations to take 3,500- 5,500 steps/day (based on 8 studies identified representing a broad range of disabilities and chronic illnesses). The authors acknowledged that these expected values were derived from an amalgamation of few and disparate studies published at that time. Further, they anticipated that these normative data would and should be modified and refined as evidence and experience using pedometers to assess physical activity would inevitably continue to accumulate.

Since that time a number of studies focused on objectively monitored data have been published and the expected values for healthy older adults have been updated \[[@B13]\]. Specifically, 28 studies published between 2001 and 2009 focusing on adults ≥50 years of age not specifically recruited for illness or disability status were identified and assembled in a review article \[[@B13]\]. Step-defined physical activity ranged from 2,000- 9,000 steps/day, was (generally) lower for women than men, appeared to decrease over reported age groups, and was lower for those defined as overweight/obese compared to normal weight samples. A separate review article \[[@B14]\] summarized expected values from 60 studies of special populations including those living with heart and vascular diseases, chronic obstructive pulmonary disease or COPD, diabetes and dialysis, breast cancer, neuromuscular diseases, arthritis, joint replacement, fibromyalgia, and disability (impaired cognitive function/intellectual difficulties). Older adults with disabilities took the lowest number of steps/day (1,214 steps/day) followed by individuals living with COPD (2,237 steps/day). The highest number of steps/day (8,008 steps/day) were taken by individuals with Type 1 diabetes, followed by those living with mental retardation/intellectual disability (7,787 steps/day) and HIV (7,545 steps/day). It is apparent that special populations, broadly defined, include those whose disability and/or chronic illness may or may not limit their mobility and/or physical endurance.

Tudor-Locke and Bassett \[[@B15]\] originally proposed a graduated step index to describe pedometer-determined habitual physical activity in adults: 1) \< 5,000 steps/day (sedentary); 2) 5,000-7,499 steps/day (low active); 3) 7,500-9,999 steps/day (somewhat active); 4) ≥ 10,000-12,499 steps/day (active); and 5) ≥12,500 steps/day (highly active). These incremental categories were reinforced in a second review in 2008 \[[@B16]\]. Recognizing a considerable floor effect (i.e., insensitivity to the range of activity levels below the lowest threshold) when applied to low active populations, Tudor-Locke et al. \[[@B17]\] suggested that the original sedentary level could be further divided into two additional incremental levels: \< 2,500 steps/day (basal activity) and 2,500- 4,999 steps/day (limited activity). As it stands, this graduated step index represents an absolute classification scheme. For example, it does not take into consideration that advancing age or the presence of chronic disease/disability generally reduces levels of activity. As such older adults and special populations will be always compared to younger populations with less disability or illness.

Table [1](#T1){ref-type="table"} displays those studies of free-living behaviour reporting the percent meeting select step-defined cut points in older adults and special populations (specifically individuals living with HIV \[[@B18]\], as no other relevant article was located on special populations). These limited studies indicate that achieving \> 10,000 steps/day is likely to be challenging for some (e.g., those taking less than 2,500 steps/day), but not necessarily impossible for all older adults (e.g., those taking more than 9,000 steps/day).

###### 

Studies of free-living behaviour reporting percent meeting select step-defined cut points in older adults

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author              Sample Characteristics                  Instrument                                                 Monitoring Frame   Cut points used           \% Meeting\
                                                                                                                                                                            Specified Cut Point
  ------------------------- --------------------------------------- ---------------------------------------------------------- ------------------ ------------------------- --------------------------------------------------------------------
  Tudor-Locke \[[@B37]\]\   6 men, 12 women;\                       Yamax Digiwalker SW-200, Yamax Corporation, Tokyo, Japan   9 days             10,000                    50% never achieved 10,000 steps on any day of the monitoring frame
  2002\                     Community dwelling older exercisers;\                                                                                                           
  Canada                    59-80 years                                                                                                                                     

                                                                                                                                                                            

  Newton \[[@B58]\]\        54 women;\                              Actigraph MTI Health Services, USA                         6 days             Adult Graded Step Index   24% \> 10,000
  2006\                     primary biliary cirrhosis patients\                                                                                                             
  UK                        63.0 ± 9.4 years                                                                                                                                

                                                                                                                                                                            

  Rowe \[[@B55]\]\          29 men, 60 women community dwelling\    Yamax\                                                     7 days             10,000                    9.6% of days \> 10,000
  2007\                     60+ years                               Actigraph                                                                                               
  UK                                                                                                                                                                        

                                                                                                                                                                            

  Ewald \[[@B88]\]\         322 men, 362 women;\                    Yamax Digwalker SW-200                                     7 days             8,000 \[[@B84]\]          Overall: 42% \> 8,000\
  2009\                     community-dwelling, urban;\                                                                                                                     55-59 year olds: 62%\
  Australia                 55 to 85 years                                                                                                                                  80+ year olds: 12%
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In summary, the updated normative data indicate that 1) apparently healthy older adults average 2,000-9,000 steps/day, and 2) special populations average 1,200-8,800 steps/day. The very broad ranges of habitual activity reflect the natural diversity of abilities common to older adults and special populations, especially given that not all chronic conditions are expected to significantly impact physical mobility and/or endurance. Further, individuals with a chronic illness are not necessarily \"older,\" further exacerbating this wide variability. Normative data continue to be published. These normative data provide an important set of reference values by which individual or group data can be compared to assumed peers. Use of a graduated step index permits classification of older adults and special populations by multiple step-defined physical activity categories. On-going surveillance of step-defined physical activity is required to track progress, identify areas of concern, and evaluate the efficacy and effectiveness of public health strategies. The next step will be to improve understanding about determinants of step-defined physical activity, including the impact of disability and chronic illness on contexts (e.g., occupation, retirement, transport, leisure, home, living arrangements, etc.) where older adults and special populations accumulate (or do not accumulate) steps, especially those of at least moderate intensity (defined below).

Interventions
-------------

Although three previous reviews have documented the effects of pedometer-based programming on physical activity \[[@B19]-[@B21]\], weight loss \[[@B19],[@B20]\], and blood pressure \[[@B19]\] in samples that have included older adults and special populations, no review has specifically examined intervention effects in either of these groups at this time. Yet these are the groups that may be most attracted to pedometer-based programming. Participants in pedometer-based community interventions delivered in Ghent, Belgium \[[@B22]\] and Rockhampton, Australia \[[@B23]\] were more likely to be older than younger. Although no actual pedometer data were reported, a library-based pedometer loan program delivered in Ontario, Canada reported that older adults (55+ years of age) were more likely to participate than other age groups.

Table [2](#T2){ref-type="table"} presents details from 13 identified pedometer-based physical activity intervention studies that have focused on older adult samples ranging in age from 55 to 95 years. The majority of participants were community-dwelling, however a few studies reported interventions with older adults living in continuing care \[[@B24]\], congregate housing \[[@B25]\], or assisted living situations \[[@B26]\]. Interventions have lasted from 2 weeks \[[@B24]\] to 11 months \[[@B27]\] in duration. The mean baseline step-defined physical activity was 4,196 steps/day (weighted mean = 3,556 steps/day); a value that is considered representative of sedentary populations \[[@B15]\]. The mean delta (i.e., difference between pre- and post-intervention) was 808 steps/day; adjusted for sample size the weighted mean delta was 775 steps/day. In comparison, a change of 2,000-2,500 steps/day is typical of pedometer-based interventions in younger adults \[[@B19],[@B21]\]. Study-specific effect sizes (Cohen\'s D) were computed where necessary data were provided in the original article, and these also appear in Table [2](#T2){ref-type="table"}. Overall, the weighted effect size was 0.26 (generally considered a small effect). This effect size is also smaller than what is expected in younger adult populations (i.e., 0.68) \[[@B21]\].

###### 

Pedometer -based physical activity intervention studies with older adults

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                  Sample                                                                         Intervention duration; study duration and design              Instrument                                                         Intervention Group\   Intervention Group\                       Delta\      Cohen\'s D
                                                                                                                                                                                                                                             Baseline Steps/day    Immediately Post-Intervention Steps/day   Steps/day   
  -------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------- ------------------------------------------------------------------ --------------------- ----------------------------------------- ----------- ------------
  Conn \[[@B89]\]\           65-96 years; community-dwelling;\                                              3-month intervention; 3-month randomized controlled trial     Yamax Digi-Walker                                                  2,773 ± 1,780         2,253 ± 1,394                             -520        -0.33
  2003\                      190 participants                                                                                                                                                                                                                                                                            
  USA                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                         

  Croteau \[[@B26]\]\        68-95 years; living in assisted living; 15 participants                        4-week intervention; 4-week quasi-experimental                Yamax Digi-Walker SW-200                                           3,031 ± 2,754         2,419 ± 2,296                             -612        -0.24
  2004\                                                                                                                                                                                                                                                                                                                  
  USA                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                         

  Jensen \[[@B90]\] 2004\    60-75 years; community -dwelling; 18 participants                              3-month intervention; 3-month quasi-experimental              Accusplit, San Jose, CA                                            4,027 ± 2,515         5,883 ± 3,214                             1,856       0.65
  USA                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                         

  Croteau \[[@B25]\] 2005\   60-90 year olds;\                                                              4- month intervention; 4-month quasi-experimental             Accusplit AX120, San Jose, California                              4,041 ± 2,824         5,559 ± 3,866                             1,518       0.45
  USA                        living in congregate housing or community-dwelling; 76 participants                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                         

  Croteau \[[@B91]\]\        55-94 years; community-dwelling; 147 participants                              12-week intervention; 12-week quasi-experimental              Yamax Digi-Walker SW-200 (Yamax Corporation, Tokyo, Japan)         4,963                 ≅ 6,200                                   ≅ 1,237     N/A
  2007\                                                                                                                                                                                                                                                                                                                  
  USA                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                         

  Sarkisian \[[@B92]\]\      ≥ 65 years; community-dwelling; 46 participants                                7-week intervention; 7-week quasi-experimental                Digiwalker (Yamax DW-500, New Lifestyles, Inc., Kansas City, MO)   3,536 ± 2,280\*       4,387 ± 2,770\*                           851         0.34
  2007\                                                                                                                                                                                                                                                                                                                  
  USA                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                         

  Wellman \[[@B93]\]\        Mean 74.6 years; community-dwelling; 320 participants                          12-week intervention; 12-week quasi-experimental              NR                                                                 3,110 ± 2,448         4,183 ± 3,257                             1,073       0.38
  2007\                                                                                                                                                                                                                                                                                                                  
  USA                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                         

  Rosenberg \[[@B24]\]\      74-92 years; living in continuing care retirement community; 12 participants   2 week intervention; 3-week quasi- experimental               Accusplit AH120M9, Pleasanton, CA                                  3,020 ± 1,858         4,246 ± 2,331                             1,226       0.59
  2008\                                                                                                                                                                                                                                                                                                                  
  USA                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                         

  Culos-Reed \[[@B94]\]\     46-83 years; community-dwelling; 39 participants                               8-week intervention; 8-week quasi-experimental                NR                                                                 5,055 ± 1,374         5,969 ± 1,543                             914         0.63
  2008\                                                                                                                                                                                                                                                                                                                  
  Canada                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                         

  Fitzpatrick \[[@B95]\]\    Mean 75 years;\                                                                4-month intervention; 4-month quasi-experimental              Accusplit, San Jose, CA                                            2,895 ± 2,170         3,743 ± 2,311                             848         0.38
  2008\                      attending senior centers;\                                                                                                                                                                                                                                                                  
  USA                        418 participants                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                         

  Opdenacker \[[@B27]\]\     ≥ 60 years; community-dwelling; 46 intervention participants                   11-month intervention; 23-month randomized controlled trial   Yamax Digiwalker SW-200, Yamax Corporation, Tokyo, Japan           7,390 ± 2,693\*\*     7,465 ± 3,344\*\*                         75          0.02
  2008\                                                                                                                                                                                                                                                                                                                  
  Belgium                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                         

  Sugden \[[@B96]\]\         70-86 years; community-dwelling;\                                              12-week intervention; 12-week randomized controlled trial     Omron HJ-005                                                       2,895                 NR                                        N/A         N/A
  2008\                      54 participants                                                                                                                                                                                                                                                                             
  U.K.                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                         

  Koizumi \[[@B97]\]\        60-78 years; community-dwelling; 34 intervention participants                  12-week intervention; 12-week randomized controlled trial     Kenz Lifecorder, Suzuken Company, Nagoya, Japan                    7,811 ± 3,268         9,046 ± 2,620                             1,235       0.42
  2009\                                                                                                                                                                                                                                                                                                                  
  Japan                                                                                                                                                                                                                                                                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Steps/day presented as mean ± SD unless otherwise noted; \*reported as steps/week in original article; divided by 7 days here; \*\*SD calculated from reported SE

Table [3](#T3){ref-type="table"} displays details from identified pedometer-based physical activity intervention studies in special populations that have reported any steps/day data. Specifically, we located 10 studies in cancer populations, three in COPD populations, two in coronary heart disease and related disorders, 15 in diabetes populations, and 3 in populations with joint or muscle disorders. Across conditions, intervention durations have ranged from 4 weeks \[[@B28],[@B29]\] to 12 months \[[@B30],[@B31]\]. Some researchers have chosen to intervene using a pedometer but to assess outcomes using an accelerometer \[[@B31]-[@B36]\]. Delta values and effect sizes were computed for each study where requisite data were reported. Additionally, we have presented unweighted and weighted (taking into consideration sample size) deltas and effect sizes by condition. Mean weighted deltas ranged from 562 steps/day for COPD to 2,840 steps/day for coronary heart disease and related disorders. Weighted effect sizes ranged from 0.06 (small) for COPD to 1.21 (large) for coronary heart disease and related disorders. Across conditions, unweighted mean delta and effect size were 2,072 steps/day and 0.64, respectively. Weighted values were 2,215 and 0.67 (medium), respectively.

###### 

Pedometer - based physical activity intervention studies with special populations

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                            Sample                                                                                                                                Intervention duration; study duration and design                                                                                     Instrument                                                                                   Intervention Group\                                                                   Intervention Group\                              Delta\               Cohen\'s D
                                                                                                                                                                                                                                                                                                                                                                                                                               Baseline Steps/day                                                                    Immediately Post-Intervention Steps/day          Steps/day            
  ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------ -------------------- --------------------
  ***Cancer***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Wilson \[[@B98]\] 2005\                              Adult breast cancer survivors; 22 intervention participants                                                                           8-week intervention;\                                                                                                                NR                                                                                           4,791                                                                                 8,297                                            3,506                N/A
  USA                                                                                                                                                                                        8-week quasi-experimental                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Pinto \[[@B32],[@B33]\]\                             Adult breast cancer survivors; 43 intervention participants                                                                           12-week intervention; 9-month randomized controlled trial                                                                            Intervention: pedometer (Yamax Digiwalker)\                                                  4,471.7 ± 5,196.1                                                                     14,571.5 ± 9,489.5                               10,100               1.38
  2005, 2009\                                                                                                                                                                                                                                                                                                                     Assessment: accelerometer (Caltrac, Muscle Dynamics, Torrance, CA)                                                                                                                                                                                       
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Vallance \[[@B99]\]\                                 Adult breast cancer survivors; 94 print materials, 94 pedometer only, 93 pedometer with print materials, 96 standard recommendation   3-month intervention; 6-month randomized controlled trial                                                                            Digi-Walker SW-200 PED (New Lifestyles Inc., Lee\'s Summit, MO)                              8,476 ± 3,248 (Pedometer only)\                                                       8,420 ± 5,226 (Pedometer only)\                  -210                 -0.06
  2007\                                                                                                                                                                                                                                                                                                                                                                                                                        7,993 ± 3,559 (Pedometer with print materials)                                        7,783 ± 3,048 (Pedometer with print materials)                        
  Canada                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Irwin \[[@B100]\]\                                   Adults with early stage breast cancer; 37 intervention participants                                                                   6-month intervention; 6-month randomized controlled trial                                                                            NR                                                                                           5,083 ± 2,313\                                                                        6,738 ± 2,958\                                   1,655                0.63
  2008\                                                                                                                                                                                                                                                                                                                                                                                                                        (based on n = 37)                                                                     (based on n = 34)                                                     
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Pinto \[[@B34]\]\                                    Breast cancer survivors; 25 intervention participants                                                                                 12-week intervention; 24-week quasi-experimental                                                                                     Intervention: pedometer (Yamax Digiwalker)\                                                  No pre-intervention steps data reported but week one mean steps/day = 515.8 ± 470.8   1,695.4 ± 1,221.3                                1,180                1.39
  2008\                                                                                                                                                                                                                                                                                                                           Assessment: accelerometer (Biotrainer-Pro, Individual Monitoring Systems, Baltimore, MD)                                                                                                                                                                 
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Matthews \[[@B35]\]\                                 Breast cancer survivors; 13 intervention participants                                                                                 12-week intervention; 12-week randomized comparative trial                                                                           Intervention: pedometer (Brand NR)\                                                          7,409.4 ± 2,791.1                                                                     8,561.8 ± 2887.3                                 1,152                0.41
  2007\                                                                                                                                                                                                                                                                                                                           Assessment: Manufacturing Technology Actigraph (MTI, Fort Walton Beach, FL, USA)                                                                                                                                                                         
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Blaauwbroek \[[@B101]\]\                             Adult survivors of childhood cancer; 38 intervention participants                                                                     10-week intervention; 36-week quasi-experimental                                                                                     Yamax digiwalker SW-200                                                                      7,653 ± 3,272                                                                         11,803 ± 3,483                                   4,150                1.23
  2009\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  The Netherlands                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Mustian \[[@B28]\]\                                  Mixed cancer type patients receiving radiation; 19 intervention participants                                                          4-week intervention; 3-month randomized controlled trial                                                                             NR                                                                                           7,222 ± 2,691                                                                         11,200 ± 5,851                                   3,978                0.93
  2009\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Swenson \[[@B30]\]\                                  Breast cancer patients receiving chemotherapy; 36 intervention participants (subsample of larger randomized trial)                    12- month intervention; 12-month quasi-experimental study conducted within a larger randomized trial                                 Walk 4 Life LS2500 (Walk 4 Life, Inc.)                                                       No pre-intervention steps data reported but week one mean steps/day = 7,453 ± 2,519   9,429 ± 3,488                                    1,976                0.66
  2010\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Unweighted mean                                  2,743                0.73

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Weighted mean                                    2,139                0.51

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  ***Chronic obstructive pulmonary disease (COPD)***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  De Blok \[[@B102]\]\                                 Adults with COPD; 8 intervention participants                                                                                         9-week intervention; 9 week randomized controlled trial                                                                              Yamax Digi-Walker SW-200 (Tokyo, Japan)                                                      2,140                                                                                 3,927                                            1,787                N/A
  2006\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  The Netherlands                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Hopses \[[@B103]\]\                                  Adults with COPD; 18 intervention participants                                                                                        12-week intervention; 12-week randomized controlled trial                                                                            Digiwalker SW-2000 (Yamax, Tokyo, Japan)                                                     7,087 ± 4,058                                                                         7,872 ± 3,962                                    785                  0.20
  2009\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  The Netherlands                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Nguyen \[[@B36]\]\                                   Adults with COPD; 8 self-monitored (SM), 9 coached (C)                                                                                6-month intervention; 6-month randomized comparative trial of cell-phone supported pedometer programs                                Intervention: Omron HJ-112 (Omron Healthcare, Bannockburn, IL, USA)\                         SM:\                                                                                  SM:\                                             SM:\                 SM: 0.02\
  2009\                                                                                                                                                                                                                                                                                                                           Assessment: Stepwatch 3 Activity Monitor (SAM; OrthoCare Innovations, Washington, DC, USA)   5,229 ± 3,021\*\                                                                      5,838 ± 3,100\*\                                 609\                 C:\
  USA                                                                                                                                                                                                                                                                                                                                                                                                                          C:\                                                                                   C:\                                              C:\                  -0.34
                                                                                                                                                                                                                                                                                                                                                                                                                               6,692 ± 3,021\*                                                                       5,675 ± 3,021\*                                  -1,017               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Unweighted mean                                  541                  0.02

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Weighted mean                                    562                  0.06

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  ***Coronary heart disease and related disorders***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  VanWormer \[[@B104]\]\                               Adults with coronary artery disease; 22 intervention participants                                                                     17-week intervention; 17-week quasi-experimental                                                                                     NR                                                                                           6,520.10 ± 2,926.99                                                                   8,210.24 ± 2,534.91                              1,690                0.62
  2004\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Izawa\                                               Adult myocardial infarction patients completing 6 months of cardiac rehabilitation;\                                                  6-month intervention; 12-month randomized controlled trial                                                                           Kenz Lifecorder, (Suzuken, Nagoya, Japan)                                                    6,564.9 ± 1,114.6                                                                     10,458.7 ± 3,310.1                               3,894                1.76
  \[[@B105]\] 2005\                                    24 intervention participants                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Japan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Unweighted mean                                  2,792                1.29

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Weighted mean                                    2,840                1.21

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  ***Diabetes and related disorders***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Tudor-Locke \[[@B29]\]\                              Adults with type 2 diabetes; 9 intervention participants                                                                              4-week intervention; 4-week quasi-experimental                                                                                       Yamax Digiwalker SW-200                                                                      6,342 ± 2,244                                                                         10,115 ± 3,407                                   3,773                1.34
  2001\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Canada                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Tudor-Locke \[[@B106]\]\                             Adults with type 2 diabetes; 24 intervention participants                                                                             16-week intervention; 24-week randomized controlled trial                                                                            Yamax SW-200, (Yamax Corporation, Tokyo, Japan)                                              5,754 ± 2,457                                                                         9,123 ± 4,539                                    3,369                0.96
  2004\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Canada                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Araiza \[[@B107]\]\                                  Adults with type 2 diabetes; 15 intervention participants                                                                             6-week intervention; 6-week; randomized controlled trial                                                                             Yamax Digiwalker SW-701 (New Lifestyles, Kansas City, MI)                                    7,220 ± 2792                                                                          10,410 ± 4,162                                   3,190                0.92
  2006\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Engel \[[@B108]\]\                                   Adults with type 2 diabetes; 30 coaching intervention, 24 pedometer intervention                                                      6-month intervention; 6-month randomized comparative trial                                                                           Yamax Digi-Walker-700                                                                        NR                                                                                    averaged 7,296 ± 2,066 during intervention       N/A                  N/A
  2006\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Australia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Richardson \[[@B109]\]\                              Adults with type 2 diabetes; 17 lifestyle goals, 13 structured goals                                                                  6-week intervention;\                                                                                                                Omron HJ-720IT (beta test version)                                                           Lifestyles goals:\                                                                    Lifestyles goals:\                               Lifestyles goals:\   Lifestyles goals:\
  2007\                                                                                                                                                                                      6-week comparative trial of two types of pedometer goal-setting strategies                                                                                                                                                        4,157 ± 1,737\                                                                        5,171 ± 1,769\                                   1,014\               0.58\
  USA                                                                                                                                                                                                                                                                                                                                                                                                                          Structured goals:\                                                                    Structured goals:\                               Structured goals:\   Structured goals:\
                                                                                                                                                                                                                                                                                                                                                                                                                               6,279 ± 3,306                                                                         6,868 ± 3,751                                    589                  0.17

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Bjorgaas \[[@B110]\]\                                Adults with type 2 diabetes; 19 intervention participants                                                                             6-month intervention;\                                                                                                               Yamax Dig-Walker ML AW-320, Yamax Corp, Tokyo, Japan                                         7,628 ± 3,715                                                                         8,022 ± 3,368                                    394                  0.11
  2008\                                                                                                                                                                                      6-month randomized controlled trial                                                                                                                                                                                                                                                                                                                                                           
  Norway                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  LeMaster \[[@B31]\]\                                 Adults with diabetic peripheral neuropathy; 41 intervention participants                                                              12-month intervention;\                                                                                                              Intervention: Accusplit Eagle 170 (Pleasanton, CA)\                                          3,335 ± 1,575\*                                                                       3,183 ± 1,537\*                                  -152                 -0.10
  2008\                                                                                                                                                                                      12-month randomized controlled trial                                                                                                 Assessment: Stepwatch 3 (Orthocare Innovations, Washington, DC)                                                                                                                                                                                          
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Cheong \[[@B111]\]\                                  Adults with type 2 diabetes; 19 pedometer-only intervention (P); 19 pedometer and low glycemic index food intake intervention (PGI)   16-week intervention; 16-week randomized comparative trial                                                                           NR                                                                                           P:\                                                                                   P:\                                              P:\                  P:\
  2009\                                                                                                                                                                                                                                                                                                                                                                                                                        5,721 ± 2,232\*\                                                                      8,527 ± 3,374\*\                                 2,806\               1.00\
  Canada                                                                                                                                                                                                                                                                                                                                                                                                                       PGI:\                                                                                 PGI:\                                            PGI:\                PGI:\
                                                                                                                                                                                                                                                                                                                                                                                                                               5,251 ± 1,944\*                                                                       9,381 ± 5,187\*                                  4,130                1.16

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Johnson \[[@B112]\]\                                 Adults with type 2 diabetes; 21 Enhanced program, 17 Basic program                                                                    12-week randomized comparative evaluation of two types of pedometer programs                                                         Digi-Walker SW-200, (Yamax, Kyoto, Japan)                                                    All participants:\                                                                    All participants:\                               1,685                0.44
  2009\                                                                                                                                                                                                                                                                                                                                                                                                                        8,948 ± 3,288                                                                         10,485 ± 4,264\*\*                                                    
  Canada                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Kirk \[[@B113]\]\                                    Adults with type 2 diabetes; 42 in-person intervention (IP),\                                                                         6-month intervention; 12-month randomized controlled trial                                                                           ActiGraph GT1M (ActiGraph LLC, Pensacola, FL, USA)                                           IP:\                                                                                  IP:\                                             IP:\                 IP:\
  2009\                                                40 written form intervention (WF)                                                                                                                                                                                                                                                                                                                                       6,600 ± 2,700\                                                                        6,500 ± 2,300\                                   -100\                -0.04\
  U.K.                                                                                                                                                                                                                                                                                                                                                                                                                         WF:\                                                                                  WF:\                                             WF:\                 WF:\
                                                                                                                                                                                                                                                                                                                                                                                                                               5,500 ± 2,300                                                                         5,300 ± 2,300                                    -200                 -0.09

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Newton \[[@B114]\]\                                  Adolescents with type 1 diabetes; 34 intervention participants                                                                        12-week intervention; 12-week randomized controlled trial                                                                            NR                                                                                           Median 11,242                                                                         Median 10,159                                    N/A                  N/A
  2009\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  New Zealand                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Tudor-Locke \[[@B115]\]\                             Adults with type 2 diabetes; 157 professional-led (PRO), 63 peer-led (PEER) participants                                              16-week intervention; 16-week quasi-experimental comparison of program delivery                                                      Yamax SW-200, (Yamax Corporation, Tokyo, Japan)                                              PRO: 3,980 ± 2,189\                                                                   PRO:\                                            PRO:\                PRO:\
  2009\                                                                                                                                                                                                                                                                                                                                                                                                                        PEER:\                                                                                7,976 ± 4,118\                                   3,996\               1.27\
  Canada                                                                                                                                                                                                                                                                                                                                                                                                                       4,396 ± 2,045                                                                         PEER:\                                           PEER:\               PEER:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     8,612 ± 3,202                                    4,216                1.61

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Vincent \[[@B116]\]\                                 Adults with type 2 diabetes; 9 intervention participants                                                                              8-week intervention; 8-week randomized controlled trial                                                                              NR                                                                                           4,175                                                                                 7,238                                            3,063                N/A
  2009\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  De Greef \[[@B72]\]\                                 Adults with type 2 diabetes; 20 intervention participants                                                                             12-week intervention, 12-week randomized controlled trial                                                                            Yamax DigiWalker SW200                                                                       7,099 ± 4,208                                                                         8,024 ± 5,331                                    925                  0.19
  2010\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Belgium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Diedrich \[[@B117]\]\                                Adults with type 2 diabetes; 11 intervention participants                                                                             3-month intervention; 3-month quasi-experiment                                                                                       Yamax Digiwalker SW-200                                                                      4,145 ± 2,929\*\*\*                                                                   6,486 ± 2,766\*\*\*                              2,341                0.82
  2010\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Unweighted mean                                  2,061                0.65

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Weighted mean                                    2,405                0.78

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  ***Joint or muscle disorders***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Talbot \[[@B118]\]\                                  Adults with knee osteoarthritis; 17 walking plus education program                                                                    12-week intervention; 12-week randomized comparative trial of a self-management education program with and without walking program   New Lifestyles Digi-walker SW-200 (Yamax, Tokyo, Japan)                                      3,519 ± 2,603                                                                         4,337 ± 2,903                                    818                  0.30
  2003\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Kilmer \[[@B119]\]\                                  Adults with neuromuscular disease; 20 intervention participants                                                                       6-month intervention; 6-month quasi-experimental home-based activity and dietary intervention                                        NR                                                                                           ≅ 4,600 (from figure)                                                                 ≅ 5,900 (from figure)                            N/A                  N/A
  2005\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Fontaine \[[@B120]\]\                                Adults with fibromyalgia syndrome; 14 intervention particpants                                                                        12-week intervention; 12-week randomized comparative trial                                                                           Accusplit Eagle Activity Pedometer (San Jose, CA)                                            2,337 ± 1,598\*                                                                       3,970 ± 2,238\*                                  1,633                0.85
  2007\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Unweighted mean                                  1,226                0.57

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Weighted mean                                    1,186                0.55
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: Values are means ± SD unless otherwise stated, personal communication with Fontaine \[[@B120]\] clarified that what was reported in the published manuscript was actually SE; COPD = Chronic obstructive pulmonary disease; \*SD calculated from reported SE; \* post-test data obtained directly from corresponding author; \*\*\*reported as steps/week in original article, divided by 7 days here.

### Controlled studies

Controlled studies conducted on treadmills or designated walking courses can provide direct information about the number of steps in continuous timed walks. The only study identified that focused on older adults was conducted by Tudor-Locke et al. \[[@B37]\] who reported that community-dwelling older adults (mean age 69 years) who were regular exercisers (confirmed by regular attendance at exercise classes that they were recruited from) took approximately 3,400 steps in a 30-minute timed group exercise walk (translating to a cadence or stepping rate of approximately 113 steps/minute) around a gymnasium. Intensity was not directly measured and it is plausible that the group nature of the walk influenced individual paces. However, the finding does fit within estimates for the number of steps taken in 30 minutes of moderate intensity walking in adults \[[@B38],[@B39]\] and within published normal cadence ranges representing \"free-speed walking\" for men (81-125 steps/minute) and women (96-136 steps/minute) aged 65-80 years \[[@B40]\]. Studies conducted with younger adult samples \[[@B41]-[@B45]\] that have directly measured the number of steps and verified activity intensity in absolute terms of metabolic equivalents or METs (1 MET = 3.5 ml O~2~/kg/min or 1 kcal/kg/hour) have concluded that, despite individual variation, a cadence of 100 steps/minute represents a reasonable heuristic value for moderate intensity walking. This suggests that 1,000 steps taken in 10 minutes of walking, or 3,000 steps taken in 30 minutes, could be used to indicate a floor value for absolutely-defined moderate intensity walking. However, it is important to note that this cadence may be unattainable for some individuals living with disability or chronic disease (including frail older adults), reflecting known differences between absolute and relative intensity with age and illness \[[@B46]\]. Unfortunately, there are no data to specifically inform absolute or relative intensity of different cadences in healthy older adults. With that being said, it is possible that *any*increase in daily step count relative to individualized baseline values could confer health benefits. This is congruent with the now accepted concept that some activity is better than none, and that some relatively important health benefits may be realized even with improvements over the lowest levels \[[@B5]\].

In a clinically-based study, 64 older subjects with peripheral artery disease (PAD) and claudication took 575 ± 105 steps to ambulate 355 ± 74 meters during a 6-minute walk test, equating to an average speed of 2.2 mph and an average cadence of 96 steps/min \[[@B47]\]. Given that these research participants were instructed to cover as much distance as possible, this average cadence represents a relatively high exercise intensity (i.e., possibly exceeding moderate intensity, at least in terms of relative intensity) in this population. This is confirmed by the results of a separate study that demonstrated that for these patients, walking at a slightly slower speed of 2.0 mph equates to an energy expenditure of approximately 70% of their peak oxygen uptake \[[@B48]\].

Walking at a cadence of 96 steps/min during a clinical test represents a much higher ambulatory challenge than that measured during free-living daily activities of PAD patients monitored for one week with a step activity monitor \[[@B49]\]. The maximum cadence for one minute of free-living ambulation (i.e., the minute with the single highest cadence value each day) averaged 90.8 steps/min, which was significantly lower than the average value of 99 steps/min in age-matched control subjects from the same study. The maximum cadence for 30 continuous minutes of ambulation each day was only 28 steps/min in PAD patients versus 35.4 steps/min in the age-matched control subjects. Thus, the cadence observed under testing conditions may not be representative of that performed during everyday life.

No other controlled study of cadence or steps taken in timed walks related to intensity was identified for any other special population group. However, the data in older adults with PAD indicate that the relative intensity of walking speeds (captured as cadence) is higher for some groups of older adults, particularly special populations living with disability or chronic illness, than for younger and healthy adults \[[@B50],[@B51]\]. Therefore, future research is needed to extend values for measured cadences, associated walking speeds, absolute intensity (MET values), and ratings of perceived exertion and/or heart rate (to assess relative intensity) in healthy older adults across a range of abilities, as well as in disease-specific populations. Although there appears to be general agreement with regards to the cadence (i.e., 100 steps/min) associated with an absolute measure of moderate intensity in younger adult samples \[[@B41]-[@B45]\], it is likely that cadence associated with relative intensity will differ between individuals in much the same manner as heart rate.

Computed step count translations for physical activity guidelines
-----------------------------------------------------------------

Physical activity guidelines from around the world do not generally recommend that older adults do less aerobic activity than younger adults \[[@B5],[@B52]\]. If anything, there seems to be even more emphasis on the importance of obtaining adequate amounts of MVPA over and above activities of daily living \[[@B3]\]. It therefore makes sense to recommend a similar step-based translation of physical activity guidelines for healthy older adults as for their younger counterparts. However, in special populations, specifically individuals (young or old) living with disability and chronic illness, it is important to promote a physically active lifestyle to the fullest extent that it is possible, even if this may fall short of general public health recommendations. For these groups where an absolute intensity or cadence interpretation may not be realistic, a shift to promoting relative intensity (and therefore relative cadence) may become increasingly important to maintain physical function and independence. In essence, for those living at the lowest levels of habitual physical activity, the clinical perspective becomes paramount and overtakes the need for more generic public health messaging.

As noted above, there is no evidence to inform a moderate intensity cadence specific to older adults at this time. However, using the adult cadence of 100 steps/minute to denote the floor of absolutely-defined moderate intensity walking, and multiplying this by 30 minutes, produces an estimate of 3,000 steps. To be a true translation of public health guidelines these steps should be taken over and above activities of daily living, be of at least moderate intensity accumulated in minimally 10 minute bouts, and add up to at least 150 minutes spread out over the week \[[@B3],[@B5],[@B53]\]. Considering a background of daily activity of 5,000 steps/day \[[@B15],[@B16]\], a computed translation of this recommendation produces an estimate of approximately 8,000 on days that include a target of achieving 30 minutes of MVPA, but approximately 7,100 steps/day if averaged over a week (i.e., 7 days at 5,000 plus 15,000 steps of at least moderate intensity). In reality, this background level of daily activity is likely to vary, and it is possible that steps/day values indicative of functional activities of daily living in some older adults (especially special populations living with disability or chronic illness) are much lower than 5,000 steps/day. Recognizing this potential, and as described above, the adult graduated step index has been extended to include \'basal activity\' (\< 2,500 steps/day) and \'limited activity\' (2,500-4,999 steps/day) \[[@B17]\]. Therefore, if we consider 2,500 steps/day as a general indicator of basal activity in older adults and/or individuals living with disability or chronic illness, the minimal estimate is 5,500 daily steps or 4,600 steps/day if averaged over a week of free-living behaviour. Admittedly, these estimates are based on assumed baseline levels, but also an increment that is tied to a cadence that has only been established as an indicator of absolutely-defined moderate-intensity walking in younger adults.

The results of the first computational strategy produce a range of 7,100- 8,000 steps/day that should be compatible with all but the most sedentary older adults (normative data indicate 2,000- 9,000 steps/day) \[[@B13],[@B14]\] and includes criterion referenced values for healthy body mass index (BMI) status related to older women (reviewed below; 8,000 steps/day for 60-94 year old women \[[@B54]\]). However, the limited interventions to date assembled in Table [2](#T2){ref-type="table"} suggest that it may be precisely these most sedentary older adults who are recruited for such pedometer-based interventions. The second strategy produces a range of approximately 4,600- 5,500 steps/day, which seems reasonable for the most sedentary older adults (i.e., those taking \< 2,500 steps/day), typically characterized as living with disability and chronic illness, but would under value the achievements of more active older adults or those with chronic illness that does not limit their physical mobility or endurance capacity. Communication using a graduated step index would span these two concerns by providing additional \"rungs on the ladder\" that take into consideration individual variability while still promoting healthful increases in physical activity. Barring health issues that might compromise abilities, there appears to be no need to otherwise reduce physical activity guidelines for apparently healthy older adults (compared to those for young to middle-aged adults). Any lower accommodation is only in recognition of anyone (including both younger adults *and*older adults) living with disabilities or chronic illness that challenge their physical abilities. It is important to emphasize that both of the computational strategies outlined above produce minimal (or threshold) estimates and it is expected that even more physical activity will be beneficial.

Direct studies of step equivalents of physical activity guidelines
------------------------------------------------------------------

Rowe et al. \[[@B55]\] studied older adults\' (60+ years of age) pedometer-determined steps/day and used a Receiver Operating Curve (ROC) analysis to inform maximal classification accuracy related to 30+ minutes of accelerometer-determined MVPA. They reported that 6,200-6,800 steps/day taken in the course of everyday life was congruent with the time-and intensity-based guidelines if discontinuous (i.e., interrupted) minutes of MVPA were accepted and 7,000-8,000 steps/day if 30 minutes of continuous (bouts ≥ 10 minutes) MVPA was required.

Aoyagi and Shephard \[[@B56]\] reviewed results of a number of studies based on the Nakanajo Study of Older Adults and shared data related to patterns of physical activity collected using an accelerometer (modified Kenz Lifecorder, Suzuken Co., Ltd., Nagoya, Aichi, Japan) that detected both steps and time in MVPA defined as \> 3 METs. They reported a strong (*r*^2^= .93) correlation between the two outputs such that those who took \< 2,000 steps/day spent almost no time in MVPA. From that point, each 1,000 step increment in daily free-living activity up to 6,000 steps/day was associated with an additional 2.5 minutes of MVPA. From 6,000- 12,000 steps/day each 1,000 step increment added another 5 minutes of MVPA. Corresponding increases in MVPA associated with an additional 1,000 steps from 12,000- 18,000 steps/day and above 18,000 steps/day were 7.5 minutes and 10 minutes, respectively. These findings indicate that 30 minutes of MVPA is associated with 10,000 steps/day in older adults (computing a running total from the details reported above). To be clear, although continuous walking performed under laboratory conditions consistently demonstrates that 1,000 steps taken continuously over 10 minutes meets the criterion for absolutely-defined moderate intensity \[[@B41]-[@B45]\], step accumulation patterns under free-living conditions include lighter intensity activities and ultimately suggest that substantially more total steps must be accrued in order to achieve recommended amounts of MVPA performed in the course of daily living.

Ayabe et al. \[[@B57]\] also used a Suzuken Lifecorder accelerometer to record both step and physical activity energy expenditure (PAEE) among cardiac rehabilitation patients. Steps/day correlated strongly with PAEE (*r*= .92) and with time spent in MVPA (*r*= .85). Achievement of minimal amounts of recommended PAEE (i.e., 1,500 kcal/week) corresponded with a daily total of 6,470 steps/day and optimal amounts (i.e., 2,200 kcal/week) corresponded with 8,496 steps/day.

In summary, the evidence suggests that, in apparently healthy older adults, taking approximately 7,000-10,000 steps/day under free-living conditions is equivalent to accumulating 30 minutes/day of MVPA (as detected by accelerometer). The only direct evidence of a steps/day equivalent of recommended amounts of MVPA that is specific to any special population (in this case, cardiac rehabilitation patients) indicates that minimal and optimal amounts of PAEE are accumulated with approximately 6,500-8,500 steps/day, respectively. The evidence to support a more specific translation of public health guidelines into steps/day for special populations is lacking. In addition, as presented above, the wide variety and types of disabilities observed in special populations may limit individual ability to perform exercise at any rigidly defined absolute moderate intensity, thus requiring a shift toward clinical strategies focused on relative goal attainment and related improvements.

Steps/day associated with various health outcomes
-------------------------------------------------

Eight cross-sectional studies have focused on older adults. Newton et al. \[[@B58]\] found that accumulating over 7,500 steps/day was related to reduced perceptions of fatigue in older women (mean age 63 years) with a diagnosis of primary biliary cirrhosis. This was the only study of steps/day associated with any health outcome identified in any special population.

Yasunaga et al. \[[@B59]\] split total values of steps/day into quartiles and reported concurrently accumulated time in MVPA (from the same instrument; Suzuken Lifecorder) and health-related quality of life (HRQoL) in older adults. They reported that HRQoL was better in the second quartile of steps/day (men: 5,500 steps/day and 13 minutes detected in moderate intensity; women: 4,500 steps/day and 14 minutes moderate intensity) compared to the first quartile but that no additional benefit (smaller and clinically insignificant improvements) was observed with higher quartiles. Although these were cross-sectional data, the authors suggested that an increase of 2,000 steps over baseline might be recommended for enhanced HRQoL in older adults. Park et al. \[[@B60]\] conducted a similar analysis, this time focused on presence vs. absence of metabolic syndrome in older adults. They reported age-range specific results. They observed a lower likelihood of metabolic syndrome in 65 to 74 year olds who took 10,000 steps/day and/or 30 minutes at \> 3 METs (also from the same instrument; Suzuken Lifecorder) and in those \> 75 years of age who took 8,000 steps/day and/or 20 minutes at \> 3 METs.

Shimuzu et al. \[[@B61]\] studied the effects of habitual physical activity determined using a pedometer on an indicator of immune functioning (salivary secretory immunoglobulin A or sIgA) in older Japanese adults (aged 65-86 years). The steps/day data were split into quartiles and the results showed that older adults who took more than approximately 7,000 steps/day also had the highest level of sIgA and this was significantly higher compared to older adults who took \< 4,600 steps/day. Mitsui et al. \[[@B62]\] also studied older (mean age 62.8 years) Japanese adults and reported that women taking 7,500-9,999 steps/day had significantly lower BMI and percent body fat than women taking \< 5,000 steps/day. Although this study failed to observe any significant difference between those taking \> 10,000 steps/day and those taking \< 5,000 steps/day, there were only 14/117 women who took \> 10,000 steps/day. Thus, this study was likely underpowered to identify small to modest differences in BMI that might exist. In addition, obesity in these older Japanese women was low (the mean BMI for the sample was 22.2 kg/m^2^). The only significant difference in health parameters observed in men in this study across step-defined physical activity was in triglycerol levels; only men who took \> 10,000 steps/day showed significantly lower values.

Foley et al. \[[@B63]\] examined the relationship between pedometer-determined steps/day and bone density at the spine and hip in older adults between 50 and 80 years of age. In men and women over age 65, the increasing difference in hip bone density ranged from 3.1% to 9.4% across the increasing steps/day quartiles. The effect on the spine was only observed in women. There was no threshold effect, that is, bone density continued to be higher with higher steps/day. In a second study of older Japanese women (age 61 to 87 years of age), Kitigawa et al. \[[@B64]\] observed a positive association (adjusted for age and weight) between ultrasound-measured calcaneus bone density and steps/day up to a maximum of 12,000 steps/day; thereafter additional steps/day were not associated with any further increase in bone density.

Tudor-Locke et al. \[[@B54]\] reported an age-specific analysis of BMI-criterion referenced and amalgamated data collected from around the world. For women aged 60-94 years of age the best cut point was 8,000 steps/day in terms of discriminating between BMI-defined normal weight and overweight/obesity. In men aged 51-88 years the value was 11,000 steps/day. The authors acknowledged that they had better confidence in the women\'s data since the men\'s value was based on a sparse sample size collected over a relatively wider age range. It is important to note that spring-levered pedometers are known to undercount steps related to obesity \[[@B65]\], so these BMI-referenced values can be questioned. However, even accelerometer-determined steps/day differ in a similar pattern across BMI-defined obesity categories \[[@B66]\]. Since pedometers are more likely to be used in clinical and public health applications, it remains important to present these pedometer-determined data as indicators of expected values in these free-living populations (that include obese individuals).

Swartz et al. \[[@B67]\] conducted a simple analysis, reporting blood pressure and fasting glucose results in older adults split by median pedometer-determined steps/day. They reported that active older adults, defined by having steps/day above the median value of 4,227 steps/day, had lower blood pressure and fasting glucose. Since a simple median split suggests only that \"more is better,\" this study cannot be used to inform the dose response relationship, nor can it be used to identify threshold values of steps/day relative to lower blood pressure or fasting glucose in older adults. Schmidt et al. \[[@B68]\] examined cardiometabolic risk, including measures of waist circumference, systolic blood pressure, fasting glucose, triglyceride, and HDL cholesterol, across the graduated step index in a sample that included older adults. They reported that individuals achieving ≥ 5,000 steps/day had a substantially lower prevalence of adverse cardiometabolic health indicators.

In summary, based on these cross-sectional studies, it appears that 4,500-5,500 steps/day is associated with higher HRQoL scores \[[@B59]\] compared to that associated with better measures of immunity (\> 7,000 steps/day \[[@B61]\]), metabolic syndrome (8,000-10,000 steps/day \[[@B60]\]), or BMI-defined weight status (8,000-11,000 steps/day \[[@B54],[@B62]\]). Dose-response relationships may also be modified by sex \[[@B62],[@B63]\]. The dose-response relationship with bone density of the hip and, at least in women, spine, appears to be linear and without threshold values \[[@B63]\]. The evidence indicating distinctly different dose-response curves related to step-defined physical activity is consistent with what was presented at a dose-response symposium \[[@B69]\] and may not be limited to older adults \[[@B70]\]. Of course, prospective and intervention studies are needed to confirm any relationship between steps/day and health outcomes. There is a general lack of any evidence relative to special populations at this time.

Discussion
==========

Monitoring steps taken is only one of many ways to track physical activity and individuals may prefer to count minutes in activity rather than wear any type of step counting device. Step counting by definition is most relevant to ambulatory activity; however, this is not the only activity that can be performed at health-related intensities. Other examples include cycling and swimming. In addition, public health guidelines categorically recognize the importance of other types of non-ambulatory activity, including resistance training \[[@B3],[@B5]\]. Therefore, the estimates contained herein are limited to translations of physical activity guidelines only in terms of ambulatory activity. For those who swim and cycle (e.g., stationary or recumbent cycling), it may be possible to consider adding \'bonus steps\' to daily totals to account for these extra non-ambulatory activities \[[@B71]\]. For example, Miller et al. \[[@B71]\] suggest adding 200 steps for every minute of non-ambulatory activities like cycling or swimming. De Greef et al. \[[@B72]\] have instructed participants in pedometer-based interventions to add 150 steps to their daily total for every minute engaged in cycling and/or swimming.

On face value, a step is the fundamental component of walking; it represents the initiation of body weight transfer and a basic expression of human mobility. Cadence, or steps/minute, is a reasonable indicator of speed \[[@B73]\] and is also related to the intensity of ambulation \[[@B41]-[@B45]\], and can theoretically capture the \"purposefulness\" of ambulatory activity. As steps are accumulated more rapidly and continuously, an individual can be said to be walking purposefully, that is, to get somewhere and/or for exercise. Of course, running is represented at the highest cadences, but this is not likely applicable to many older adults or individuals living with disability or chronic illness. As mentioned above, 100 steps/minutes is a cadence that is growing in acceptance as a heuristic value indicative of walking at an absolutely-defined intensity of 3 MET intensity, at least in younger adults \[[@B41]-[@B45]\]. This cadence may be unrealistic for many older adults (especially for those who are more frail) or for those living with disability or chronic illness. It may be useful to embrace a \"something is better than nothing\" approach \[[@B5]\], or even a \"better than usual\" approach, in terms of setting relative goals for such special populations.

The correlation between age and preferred walking speed in a population study of older adults 60-86 years of age was -.34 (women) and -.41 (men) \[[@B74]\]. Those living with disability or chronic illness may walk at even slower speeds \[[@B75]\]. Overall, aging, disabled, and ill older adults may gradually lose their ability to walk at higher cadences and what remains is the \"pottering\" (i.e., random, unplanned movements) associated with activities of daily living that all ages appear to engage in to some extent \[[@B76]\]. Slow walking speed in older adults is strongly associated with increased risk of cardiovascular mortality \[[@B77]\]. Since public health guidelines for older adults continue to emphasize the importance of engagement in aerobic activities that are of at least moderate intensity, it follows that any step count translation also reflects this emphasis. Although pedometers have been widely criticized for not being sensitive to detecting slow walking, their ability to \"censor\" low force accelerations might actually be seen as a feature that permits a concerted focus on only those steps that are more likely to be beneficial to health \[[@B78]\].

Regardless, the interest in detecting even very low force accelerations is evident from research studies focused on physical activity behaviours of older adults \[[@B13],[@B79]\] and especially of individuals living with disability and chronic illness \[[@B14]\] that have been adopting the StepWatch Activity Monitor (SAM, CYMA Corporation, Mountlake Terrace, WA). The SAM is an ankle worn-accelerometer that detects a \"stride\" or \"gait cycle.\" To be interpreted relative to more traditional waist-mounted instruments (both accelerometers and pedometers), its output needs to be doubled and expressed as steps. However, this instrument is designed to be exceptionally sensitive to slow gaits \[[@B80]\] (and is also more likely to detect \"fidgeting\" activities \[[@B80]\]) and therefore its output would appear higher than that of more traditional pedometers \[[@B17]\]. For example, a sample of older adults (mean age 83 years) who wore the SAM for 6 consecutive days averaged approximately 10,000 steps/day \[[@B81]\], or \'active\' if directly (and inappropriately) interpreted against the graduated step index based on pedometer output \[[@B15],[@B16]\]. The SAM remains an important research tool, however, it is less practical for public health applications. No conversion factor exists at this time to assist in translation of SAM-detected steps to that of pedometers that have been more traditionally used in research and practice.

Another instrument, the ActiGraph accelerometer, is also known to be more sensitive to lower force accelerations (\[[@B82]-[@B84]\]) and its output from earlier models needed to be manipulated in order to interpret it against existing pedometer-based scales \[[@B15],[@B16]\]. More recently, the manufacturers of this instrument have offered a \'low extension\' option that can be selected, or deselected, depending on sensitivity requirements. Since pedometers are more likely to be adopted by a range of users including researchers, practitioners, and the general public, and since public health guidelines specifically emphasize MVPA (and not lighter intensity activities), the step-based translations presented in this article are intentionally more reflective of what would be expected from the use of good quality pedometers. Although the need to detect less forceful steps, especially in some clinical populations can be justified, it remains a concern that comparisons between datasets collected with different devices are hampered unless acceptable conversion factors to facilitate such interpretation can be determined.

Regardless of the choice of instrumentation, normative step values for older adults and special populations span a very wide range. Although the graduated step index described above offers a definite improvement over evaluation using any single step value (e.g., 10,000 steps/day), even smaller increments would provide additional \"rungs on the ladder\" and represent a more continuous and fully expanded steps/day scale. Specifically, 1,000 step increments \[[@B41]-[@B45]\] are congruent with the concept of 10-minute bouts taken at 100 steps/min or minimally moderate intensity \[[@B3],[@B5]\], and three 10-minutes bouts (i.e., 3 × 1,000 steps = 3,000 steps) are congruent with a daily 30-minute minimally moderate intensity physical activity recommendation. Figure [1](#F1){ref-type="fig"} presents the fully expanded steps/day scale. The scale begins at zero and continues to 18,000+ steps/day, representing the single highest average value reported for a sample at this time in Amish men \[[@B85]\]. Although all age groups are represented, the one-way arrows identify step-based translations of population-specific public health guidelines contained herein (and separately reviewed in companion papers) but also suggest that more is better. For example, the range for healthy older adults is 7,000-10,000 steps/day, at least 3,000 of which should be accumulated at a brisk pace. For individuals living with disability or chronic illness the range is 6,500-8,500 steps/day (although this is based on limited evidence at this time). The difference between thresholds for adults 20-65 years of age and healthy older adults 65+ years of age is nominal (i.e., approximately 300 steps), but it is based on the empirical evidence assembled, and suggests that apparently healthy older adults are capable of achieving minimum steps/day for improving health. However, quite clearly there is a larger gap at the upper end, which reflects decreasing capacity with age (and disease and disability) to achieve upper-end targets. Again, it is important to emphasize, that the oldest-old, especially those compromised by frailty, are more likely to be described as a special population where a clinical approach to increasing physical activity will more appropriately supersede a public health approach. Regardless, adoption of this fully expanded steps/day scale applied across the lifespan would facilitate communication, evaluation, and research. As evidence accumulates, it may be possible to locate population-specific likelihoods of achieving valued health-related outcomes along the scale.

![**Steps/day scale schematic linked to time spent in MVPA**.](1479-5868-8-80-1){#F1}

An important limitation must be emphasized. It is well known that the measurement mechanism of accelerometers is more sensitive to lower force accelerations (e.g., slow walking) and therefore this type of instrumentation will detect more steps than simple pedometers. However, there are no data at this time to inform us about the health value of steps taken at very low intensity steps independent of higher intensity steps. Indeed, perhaps one contributory factor to age-related decline is the decrease in intensity of daily movement and the progressive loss of higher intensity movements. This is speculative. Regardless, the difference in instrument sensitivity makes it so that the output of accelerometers should generally not be directly interpreted against the scaling presented herein. A direct conversion factor between instruments is not known at this time, but would certainly be useful. The continued use of BMI as a useful, albeit imperfect, indicator of body fatness is an appropriate analogy to the use of a pedometer as an indicator of healthful levels of physical activity. Regardless, any step-based translation of current physical activity guidelines should clearly convey the importance of making an appropriate portion of daily steps congruent with undertaking recommended amounts and bouts of MVPA \[[@B86],[@B87]\].

Conclusions
===========

The very broad ranges of habitual activity evident from normative data reflect the natural diversity of physical capacity common to older adults and special populations. There is no evidence to inform an absolutely-defined moderate intensity cadence specific to older adults at this time. However, using the adult cadence of 100 steps/minute to denote the floor of absolutely-defined moderate intensity walking, and multiplying this by 30 minutes produces a reasonable heuristic value of 3,000 steps. To be a true translation of public health guidelines these steps should be taken over and above activities of everyday living, be of at least moderate intensity accumulated in minimally 10 minute bouts (i.e., at least 1,000 steps taken at a cadence of 100 steps/min), and add up to at least 150 minutes spread out over the week. Computed translations of this recommendation approximate 8,000 daily steps and 7,100 steps/day if averaged over a week. Directly measured estimates of free-living activity that include recommended amounts of MVPA are not too different: 7,000 -10,000 steps/day. Recognizing that the most sedentary older adults and individuals living with disability and chronic illness may be more limited in their everyday activities, but could still benefit from a physically active lifestyle, a similarly computed translation approximates 5,500 daily steps or 4,600 steps/day if averaged over a week of free-living behaviour. Direct evidence (measured objectively by accelerometer) suggests a somewhat higher range (6,500- 8,500 steps/day), however, it is important to remember that this is based on a single study of patients in a cardiac rehabilitation program. Direct evidence is urgently needed for other special populations. Individuals living with more physically limiting conditions may demonstrate lower normative values and thus may benefit from more individualized daily step targets relative to their unique baseline values. Health outcome-referenced values of steps/day appear to differ in older adults depending upon which health-related outcome is desired. All estimates herein express translations of minimal recommendations, and more is likely better.
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